|
1
|
Vale W, Spiess J, Rivier C and Rivier J:
Characterization of a 41-residue ovine hypothalamic peptide that
stimulates secretion of corticotropin and beta-endorphin. Science.
213:1394–1397. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sakamoto R, Matsubara E, Nomura M, Wang L,
Kawahara Y, Yanase T, Nawata H and Takayanagi R: Roles for
corticotropin-releasing factor receptor type 1 in energy
homeostasis in mice. Metabolism. 62:1739–1748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grammatopoulos DK: Insights into
mechanisms of corticotropin-releasing hormone receptor signal
transduction. Br J Pharmacol. 166:85–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanna-Mitchell AT, Wolf-Johnston A,
Roppolo JR, Buffington TC and Birder LA: Corticotropin-releasing
factor family peptide signaling in feline bladder urothelial cells.
J Endocrinol. 222:113–121. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hillhouse EW and Grammatopoulos DK: The
molecular mechanisms underlying the regulation of the biological
activity of corticotropin-releasing hormone receptors: Implications
for physiology and pathophysiology. Endocr Rev. 27:260–286. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nozu T, Tsuchiya Y, Kumei S, Takakusaki K
and Okumura T: Peripheral corticotropin-releasing factor (CRF)
induces stimulation of gastric contractions in freely moving
conscious rats: Role of CRF receptor types 1 and 2.
Neurogastroenterol Motil. 25:190–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma S, Shen Q, Zhao LH, Mao C, Zhou XE,
Shen DD, de Waal PW, Bi P, Li C, Jiang Y, et al: Molecular basis
for hormone recognition and activation of corticotropin-releasing
factor receptors. Mol Cell. 77:669–680.e664. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fekete EM and Zorrilla EP: Physiology,
pharmacology, and therapeutic relevance of urocortins in mammals:
Ancient CRF paralogs. Front Neuroendocrinol. 28:1–27. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
LaBerge J, Malley SE, Zvarova K and
Vizzard MA: Expression of corticotropin-releasing factor and CRF
receptors in micturition pathways after cyclophosphamide-induced
cystitis. Am J Physiol Regul Integr Comp Physiol. 291:R692–R703.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saban MR, Nguyen NB, Hammond TG and Saban
R: Gene expression profiling of mouse bladder inflammatory
responses to LPS, substance P, and antigen-stimulation. Am J
Pathol. 160:2095–2110. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jhang JF, Birder LA, Jiang YH, Hsu YH, Ho
HC and Kuo HC: Dysregulation of bladder corticotropin-releasing
hormone receptor in the pathogenesis of human interstitial
cystitis/bladder pain syndrome. Sci Rep. 9:191692019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kaprara A, Pazaitou-Panayiotou K,
Kortsaris A and Chatzaki E: The corticotropin releasing factor
system in cancer: Expression and pathophysiological implications.
Cell Mol Life Sci. 67:1293–1306. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tezval H, Jurk S, Atschekzei F, Becker JU,
Jahn O, Serth J and Kuczyk MA: Urocortin and
corticotropin-releasing factor receptor 2 in human renal cell
carcinoma: Disruption of an endogenous inhibitor of angiogenesis
and proliferation. World J Urol. 27:825–830. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tezval H, Jurk S, Atschekzei F, Serth J,
Kuczyk MA and Merseburger AS: The involvement of altered
corticotropin releasing factor receptor 2 expression in prostate
cancer due to alteration of anti-angiogenic signaling pathways.
Prostate. 69:443–448. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jin L, Zhang Q, Guo R, Wang L, Wang J, Wan
R, Zhang R, Xu Y and Li S: Different effects of
corticotropin-releasing factor and urocortin 2 on apoptosis of
prostate cancer cells in vitro. J Mol Endocrinol. 47:219–227. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dahm P and Gschwend JE: Malignant
non-urothelial neoplasms of the urinary bladder: A review. Eur
Urol. 44:672–681. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
World Medical Association: World Medical
Association Declaration of Helsinki: ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sylvester RJ, Rodríguez O, Hernández V,
Turturica D, Bauerová L, Bruins HM, Bründl J, van der Kwast TH,
Brisuda A, Rubio-Briones J, et al: European association of urology
(EAU) prognostic factor risk groups for non-muscle-invasive bladder
cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973
classification systems for grade: An update from the EAU NMIBC
guidelines panel. Eur Urol. 79:480–488. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Poulaki S, Rassouli O, Liapakis G,
Gravanis A and Venihaki M: Analgesic and anti-inflammatory effects
of the synthetic neurosteroid analogue BNN27 during CFA-induced
hyperalgesia. Biomedicines. 9:11852021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang C, Wang YQ, Jin G, Wu S, Cui J and
Wang RF: Selection of reference genes for gene expression studies
in human bladder cancer using SYBR-Green quantitative polymerase
chain reaction. Oncol Lett. 14:6001–6011. 2017.PubMed/NCBI
|
|
21
|
De Spiegelaere W, Dern-Wieloch J, Weigel
R, Schumacher V, Schorle H, Nettersheim D, Bergmann M, Brehm R,
Kliesch S, Vandekerckhove L and Fink C: Reference gene validation
for RT-qPCR, a note on different available software packages. PLoS
One. 10:e01225152015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikeda K, Akiyoshi K, Kamada M, Fujioka K,
Tojo K and Manome Y: Expression of urocortin I in normal tissues
and malignant tumors. Cancer Cell & Microenvironment. 1:45–50.
2014.PubMed/NCBI
|
|
23
|
Owens GL, Lawrence KM, Jackson TR, Crosbie
EJ, Sayan BS, Kitchener HC and Townsend PA: Urocortin suppresses
endometrial cancer cell migration via CRFR2 and its system
components are differentially modulated by estrogen. Cancer Med.
6:408–415. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Graziani G, Tentori L, Portarena I,
Barbarino M, Tringali G, Pozzoli G and Navarra P: CRH inhibits cell
growth of human endometrial adenocarcinoma cells via CRH-receptor
1-mediated activation of cAMP-PKA pathway. Endocrinology.
143:807–813. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carlson KW, Nawy SS, Wei ET, Sadée W,
Filov VA, Rezsova VV, Slominski A and Quillan JM: Inhibition of
mouse melanoma cell proliferation by corticotropin-releasing
hormone and its analogs. Anticancer Res. 21:1173–1179.
2001.PubMed/NCBI
|
|
26
|
Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang
G and Li S: Urocortin's inhibition of tumor growth and angiogenesis
in hepatocellular carcinoma via corticotrophin-releasing factor
receptor 2. Cancer Invest. 26:359–368. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reyes TM, Lewis K, Perrin MH, Kunitake KS,
Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW and
Sawchenko PE: Urocortin II: A member of the corticotropin-releasing
factor (CRF) neuropeptide family that is selectively bound by type
2 CRF receptors. Proc Natl Acad Sci USA. 98:2843–2848. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ou Y, Zheng X, Gao Y, Shu M, Leng T, Li Y,
Yin W, Zhu W, Huang Y, Zhou Y, et al: Activation of cyclic AMP/PKA
pathway inhibits bladder cancer cell invasion by targeting
MAP4-dependent microtubule dynamics. Urol Oncol. 32:47.e21–48.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goto T and Miyamoto H: The role of
estrogen receptors in urothelial cancer. Front Endocrinol
(Lausanne). 12:6438702021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stewart TA, Yapa KT and Monteith GR:
Altered calcium signaling in cancer cells. Biochim Biophys Acta.
1848:2502–2511. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cai H, Chiorean EG, Chiorean MV, Rex DK,
Robb BW, Hahn NM, Liu Z, Loehrer PJ, Harrison ML and Xu Y: Elevated
phospholipase A2 activities in plasma samples from multiple
cancers. PLoS One. 8:e570812013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kopparapu PK, Boorjian SA, Robinson BD,
Downes M, Gudas LJ, Mongan NP and Persson JL: Expression of VEGF
and its receptors VEGFR1/VEGFR2 is associated with invasiveness of
bladder cancer. Anticancer Res. 33:2381–2390. 2013.PubMed/NCBI
|
|
33
|
Paner GP, Ro JY, Wojcik EM, Venkataraman
G, Datta MW and Amin MB: Further characterization of the muscle
layers and lamina propria of the urinary bladder by systematic
histologic mapping: Implications for pathologic staging of invasive
urothelial carcinoma. Am J Surg Pathol. 31:1420–1429. 2007.
View Article : Google Scholar : PubMed/NCBI
|
